Dr. Jessica Robin
As the Director of Clinical Research at Winterlight Labs, Jessica leads the clinical research program, aimed at developing and validating novel speech-based biomarkers for health research. Winterlight's mission is to develop speech processing technology and natural language processing tools to give insight into patient health in a more accessible and less intrusive way. Jessica oversees study design, data collection, designs analysis plans and helps to communicate the results of Winterlight's studies relating to how speech and language are affected in neurodegenerative disease and psychiatric disorders. Jessica has training in cognitive neuroscience, psychology and linguistics and over ten years experience conducting neuroscientific research. She completed a Bachelor’s of Arts & Science with an interdisciplinary major in Cognitive Science at McGill University. She then completed a Master’s and PhD in cognitive neuroscience at the University of Toronto, with a focus on the cognitive neuroscience of memory and spatial cognition and funding from the Natural Sciences and Engineering Research Council of Canada. Following her PhD, Jessica completed a postdoctoral fellowship at the Rotman Research Institute at Baycrest Hospital, and was funded by the Alzheimer Society of Canada to study early signs of cognitive impairment using methods including structural and functional neuroimaging, eye-tracking and cognitive testing.
Friday April 8, 2022
Are You Listening? Using speech to detect cognitive decline and depression
Speech contains information about our health, cognition and mood. Advancements in automated speech processing technology have the potential to help us develop novel tools to measure these patterns and potentially allow for early diagnosis or better tracking of neurologic and psychiatric disease and disorders. Winterlight Labs is developing tools to detect dementia and depression from speech. In this talk, I will provide an overview of our technology and our research in developing and validating digital speech-based biomarkers.